Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
NCT02038049 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2021-01-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFRSF13C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-19Phase 3 first posted: Novartis Pharmaceuticals, ianalumab s.c. q4w + ianalumab s.c. q12w (NCT05126277)
- 2021-10-08Also stopped (terminated): Novartis Pharmaceuticals, VAY736 + Placebo (NCT01930175)
- 2020-10-19Results posted on the registry: Novartis Pharmaceuticals, VAY736 + Placebo (NCT01930175)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision